Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=22 Incretins in Impaired Fasting Glucose
Pre-diabetes
Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05
N/A N=26 Incretin Effect in People With Impaired Fasting Glucose
Obesity
Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
N/A N=1,939 Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care
Type 2 Diabetes Mellitus · Prediabetic State
Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…
N/A N=21 Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth
Obesity · Impaired Glucose Tolerance · Type 2 Diabetes Mellitus
Primary: Mean Percent Change From Baseline in Whole-body Insulin Sensitivity — 87.4; 63.1 percentage of change from baseline
N/A N=39 Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Prediabetic State
Primary: Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose…
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=70 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
Impaired Glucose Tolerance · Prediabetic State
Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943
Phase 2 N=57 Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes
Diabetes, Gestational
Primary: Correlation Between Glucose AUC and Birth Weight. — 0.2902; 0.2935; 0.2915; 0.2859 correlation coefficient — p=0.035
N/A N=28 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Acromegaly · Type 2 Diabetes Mellitus
Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants
Phase 3 N=202 Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance
Impaired Glucose Tolerance
Primary: Change 2-hour Plasma Glucose (During Oral Glucose Tolerance Test). — 9.27; 9.11; 7.28; 8.32 mmol/L — p=0.0028
N/A N=200 Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy
Gestational Diabetes · Diagnoses Disease · Pregnancy in Diabetic
Primary: Number of Participants With a Positive Gestational Diabetes Mellitus (GDM) Screen (>= 140 mg/dL) on the 1 Hour 50-g Oral Glucose Tolerance Test (OGTT) — 31; 13…
Phase 2 N=12 The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Insulin Secretion — 56766 pmol/l * 90 minutes
Phase 3 N=602 Actos Now for Prevention of Diabetes (ACT NOW)
Impaired Glucose Tolerance · Type 2 Diabetes
Primary: Prevention of Type 2 Diabetes — 16.1; 5.0 percentage of participants
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
N/A N=958 Gestational Diabetes Mellitus Trial (GDM)
Diabetes, Gestational
Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14
N/A N=95 Early Screening and Treatment of Women With Prediabetes in Pregnancy
Diabetes · Pregnancy
Primary: Number of Patients With a Diagnosis of Gestational Diabetes at 26 Weeks Gestation. — 19; 23 Participants — p=0.32
N/A N=38 Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance
Impaired Glucose Tolerance
Primary: Post Meal Glucose Area Under the Curve — 508; 513 mg*hr/dL
N/A N=962 Early Gestational Diabetes Screening in the Gravid Obese Woman
Gestational Diabetes · Obesity
Primary: Number of Participants With a Composite Perinatal Outcome — 235; 261 Participants
N/A N=51 The Relationship Between Sleep and Glucose Tolerance in Prediabetes: the Role of GLP-1 in Short Sleepers
Prediabetes
Primary: GLP-1 Levels in Response to Oral Glucose Tolerance Test — 16.66; 18.57 pmol/l.h — p=0.209
N/A N=90 Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus
Gestational Diabetes Mellitus
Primary: The Concentration of Serum FGF19 — 65.96; 124.47 pg/mL
Phase 2 N=91 A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Fasting Plasma Glucose at Day 1 — 0.20; 0.39; -0.96; -0.47 mmol/L — p=0.2790
Phase 2 N=30 Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose (FPG) — 5.8; 5.5 mmol/L — p=0.004
Phase 1 N=36 Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)
Hypertension
Primary: Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT) — 3.44; 3.55 ng/minute — p=0.067
N/A N=24 Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion
Glucose Intolerance
Primary: Postprandial Glucose Levels at Week 12 — 9.5; 9.9 mmol/L — p=0.380
N/A N=44 Effect of Fermentable Carbohydrate on Glucose Homeostasis
Prediabetes
Primary: Glycaemic Control — -0.23; 0.44 mmol//l — p=0.005
Phase 4 N=20 Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment
Schizophrenia
Primary: Change From Baseline in Insulin Sensitivity — 3.2; 0.4 microUnits/mL — p=0.08
Phase 3 N=21 Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
Impaired Fasting Glucose · Prediabetes
Primary: Acute Insulin Response (AIRg) to Intravenous Glucose — 1866; 1752 pmol/1*min
Phase 1 N=22 Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Insulin Resistance, Diabetes
Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146